KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to 0.03%.

  • Supernus Pharmaceuticals' Return on Capital Employed fell 900.0% to 0.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.03%, marking a year-over-year decrease of 900.0%. This contributed to the annual value of 0.08% for FY2024, which is 800.0% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Return on Capital Employed is 0.03%, which was down 900.0% from 0.06% recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Return on Capital Employed registered a high of 0.12% during Q1 2021, and its lowest value of 0.03% during Q3 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median Return on Capital Employed value was 0.05% (recorded in 2022), while the average stood at 0.05%.
  • In the last 5 years, Supernus Pharmaceuticals' Return on Capital Employed soared by 800bps in 2024 and then tumbled by -900bps in 2025.
  • Supernus Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.07% in 2021, then plummeted by -31bps to 0.05% in 2022, then tumbled by -112bps to 0.01% in 2023, then soared by 1545bps to 0.08% in 2024, then crashed by -145bps to 0.03% in 2025.
  • Its Return on Capital Employed was 0.03% in Q3 2025, compared to 0.06% in Q2 2025 and 0.07% in Q1 2025.